Recent Updates
Recently added Catalysts
CVAC

Execution Version PURCHASE AGREEMENT dated as of

Key Takeaway: Article 1 DEFINITIONS Section 1.01 Definitions 2 Section 1.02 Other Definitional and Interpretative Provisions 22 Article 2 THE OFFER Section 2.01 The Offer 22 Section 2.02 Company Action 27 Section 2.03 Equity Awards 28 Section 2.04 Extraordinary General Meeting 29 Section 2.05

Full Press Release Details

Article 1
DEFINITIONS
Section 1.01 Definitions 2
Section 1.02 Other Definitional and Interpretative Provisions 22
Article 2
THE OFFER
Section 2.01 The Offer 22
Section 2.02 Company Action 27
Section 2.03 Equity Awards 28
Section 2.04 Extraordinary General Meeting 29
Section 2.05 Directors 32
Section 2.06 Further Actions 34
Section 2.07 Post-Offer Reorganization 34
Section 2.08 Exchange of Company Shares. 36
Section 2.09 Adjustments 39
Section 2.10 Withholding 39
Section 2.11 Transfer Taxes 40
Article 3
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
Section 3.01 Corporate Existence and Power 40
Section 3.02 Corporate Authorization 40
Section 3.03 Governmental Authorization 41
Section 3.04 Non-contravention 41
Section 3.05 Capitalization 42
Section 3.06 Subsidiaries 44
Section 3.07 SEC Filings 45
Section 3.08 Financial Statements 46
Section 3.09 Internal Controls 46
Section 3.10 Disclosure Documents 47
Section 3.11 Absence of Certain Changes 48
Section 3.12 No Undisclosed Liabilities 48
Section 3.13 Compliance with Laws; Regulatory Matters; Healthcare Laws; Subsidies 49
Section 3.14 Litigation 51
Section 3.15 Properties 52
Section 3.16 Intellectual Property; Privacy and Data Protection 53
Section 3.17 Taxes 59
Section 3.18 Tax Free Reorganization Matters 61
Section 3.19 Employee Benefit Plans 61
Section 3.20 Employee and Labor Matters 63
Section 3.21 Environmental Matters 66
Section 3.22 Material Contracts 67
Section 3.23 Financial Advisor Fees 70
Section 3.24 Opinion of Company Financial Advisor 70
Section 3.25 Insurance 70
Section 3.26 Anti-Takeover Measures 71
Section 3.27 Information Supplied 71
Section 3.28 Related Party Transactions 71
Section 3.29 Rule 14d-10 Matters 71
Section 3.30 No Other Representations and Warranties 72
Article 4
REPRESENTATIONS AND WARRANTIES OF BUYER
Section 4.01 Corporate Existence and Power 73
Section 4.02 Corporate Authorization 73
Section 4.03 Governmental Authorization 73
Section 4.04 Non-Contravention 73
Section 4.05 Capitalization 74
Section 4.06 SEC Filings 74
Section 4.07 Financial Statements 75
Section 4.08 Internal Controls 76
Section 4.09 Disclosure Documents 76
Section 4.10 Absence of Certain Changes 77
Section 4.11 No Undisclosed Liabilities 77
Section 4.12 Litigation 78
Section 4.13 Ownership of Company Shares; Investment 78
Section 4.14 Tax-Free Reorganization Matters. 78
Section 4.15 Absence of Certain Agreements 78
Section 4.16 No Other Representations and Warranties 79
Article 5
COVENANTS OF THE COMPANY
Section 5.01 Conduct of the Company 79
Section 5.02 Access to Information 84
Section 5.03 No Solicitation; Adverse Recommendation Change 85
Section 5.04 Compensation Arrangements 89
Section 5.05 Delisting; Deregistration 90
Section 5.06 Anti-Takeover Measures 90
Section 5.07 Internal Controls Remediation Actions 90
Section 5.08 Tax Matters 90
Article 6
COVENANTS OF BUYER
Section 6.01 Director and Officer Liability 91
Section 6.02 Employee Matters 92
Section 6.03 Stock Exchange Listing 94
Section 6.04 Conduct of Buyer 94
Section 6.05 Tax Matters 95
Article 7
COVENANTS OF THE PARTIES
Section 7.01 Regulatory Approvals; Efforts 95
Section 7.02 Certain Filings 98
Section 7.03 Further Assurances 98
Section 7.04 Public Announcements 98
Section 7.05 Notices of Certain Events 99
Section 7.06 Litigation 100
Section 7.07 Business Continuity 100
Section 7.08 Tax Free Reorganization Matters 100
Article 8
TERMINATION
Section 8.01 Termination 101
Section 8.02 Effect of Termination 103
Section 8.03 Expenses; Termination Compensation 104
Section 8.04 Buyer Termination Compensation 104
Article 9
MISCELLANEOUS
Section 9.01 Notices 106
Section 9.02 Non-Survival of Representations and Warranties; Survival of Certain Covenants and Agreements 108
Section 9.03 Amendments and Waivers 108
Section 9.04 Rules of Construction 108
Section 9.05 Assignment 108
Section 9.06 Governing Law 109
Section 9.07 Dispute Resolution 109
Section 9.08 Counterparts; Electronic Delivery; Effectiveness 110
Section 9.09 Entire Agreement; No Third-Party Beneficiaries 111
Section 9.10 Severability 111
Section 9.11 Specific Performance 111
- Form of Legal Downstream Merger Deed
B-1 and B-2 - Form of Legal Downstream Merger Proposal and Notes
- Form of Post-Downstream Merger Share Sale Agreement
PURCHASE AGREEMENT (this "Agreement") dated as of June 12, 2025, by and between BioNTech SE, a European
stock corporation (Societas Europaea) organized under the Laws of Germany and the European Union registered with the commercial
register at the district court of Mainz under HRB 48720 ("Buyer"), and CureVac N.V., a public limited liability
company (naamloze vennootschap) organized under the Laws of The Netherlands, having its registered office (statutaire zetel)
in Amsterdam, The Netherlands, registered with the Dutch trade registered under number 77798031 (the "Company").
W I T N E S S E T H:
WHEREAS, Buyer desires to acquire the Company on
the terms and subject to the conditions set forth in this Agreement;
the management board of the Company (the "Management Board") and the supervisory board of the Company (the "Supervisory
Board" and together with the Management Board, the "Company Boards") have (i) determined that, on the
terms and subject to the conditions set forth in this Agreement, this Agreement and the Signing Transactions, are in the best interest
of the Company and the sustainable success of its business, having considered the interest of its shareholders, employees and other relevant
stakeholders, (ii) approved the terms and conditions of this Agreement and the Signing Transactions and the execution, delivery and
performance of the Company's obligations under this Agreement and (iii) unanimously resolved, on the terms and subject to the
conditions set forth in this Agreement, to support the Offer, to recommend acceptance of the Offer by the shareholders of the Company
and to recommend approval and adoption of the resolutions set forth in Section 2.04(a);
WHEREAS, the management board and the supervisory
board of Buyer have each unanimously determined that, on the terms and subject to the conditions set forth in this Agreement, this Agreement
and the Transactions are in the best interests of Buyer and all of its stakeholders and have approved the execution, delivery and performance
of this Agreement and the consummation of the Transactions;
Buyer shall commence an exchange offer (as it may be amended from time to time as permitted by this Agreement, the "Offer")
to purchase any (subject to the Minimum Condition) and all of the ordinary shares, par value 0.12 per share, of the Company (collectively,
the "Company Shares") for the consideration and upon the terms and subject to the conditions set forth herein;
concurrently with the execution and delivery of this Agreement, and as a condition of and inducement to Buyer's willingness to enter
into this Agreement, certain shareholders of the Company are executing and delivering tender and support agreements to the Buyer pursuant
to which those shareholders, among other things, agree with the Buyer to tender all Company Shares beneficially owned by them or their
controlled Affiliates to Buyer in response to the Offer (together with any similar agreements that may be signed after the date of this
Agreement, the "Tender and Support Agreements");
WHEREAS, each of the parties intends that, for
U.S. federal income tax purposes, the Offer, taken together with the Legal Downstream Merger, the Post-Downstream Merger Share Sale, the
Cancellation, and the New Topco U.S. Tax Election, will qualify as one or more "reorganizations" within the meaning of Section 368(a) of
the Code and the Treasury Regulations, and this Agreement is intended to constitute a "plan of reorganization" within the
meaning of Section 368 of the Code and the Treasury Regulations; and
WHEREAS, Buyer and the Company desire to make certain
representations, warranties, covenants and agreements in connection with this Agreement.
NOW, THEREFORE, in consideration of the foregoing
and the representations, warranties, covenants and agreements contained in this Agreement, the Parties agree as follows:
Section 1.01 Definitions.
As used in this Agreement, the following terms have the following meanings:
"1933 Act" means the United
States Securities Act of 1933, as amended.
"1934 Act" means the United
States Securities Exchange Act of 1934, as amended.
"Acceptable Confidentiality Agreement"
shall have the meaning set forth in Section 5.03(b)(i).
"Acceptance Time" shall have
the meaning set forth in Section 2.01(b).
"Action" means any litigation,
action, claim, complaint, investigation, suit, hearing, arbitration, mediation, interference, cancellation, opposition, reexamination
or other proceeding (public or private) by or before, or otherwise involving, any Governmental Authority.
"Adverse Recommendation Change"
shall have the meaning set forth in Section 5.03(d)(i).
"Affiliate" means, with respect
to any Person, any other Person directly or indirectly controlling, controlled by or under common control with such Person. For purposes
of this definition, the term "control" (including the correlative terms "controlling," "controlled by"
and "under common control with") means the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
"Affiliate Agreement" shall
have the meaning set forth in Section 3.28.
"Aggregate Withholding Amount"
shall have the meaning set forth in Section 2.08(i).
"Agreement" shall have the meaning
set forth in the Preamble.
"Alternative Acquisition Agreement"
shall have the meaning set forth in Section 5.03(d).
Acquisition Proposal" means any inquiry, proposal, indication of interest or offer from any Person or group of Persons (or the
shareholders of any Person) other than Buyer and its Subsidiaries and Affiliates (such Person or group (or such shareholders), a "Company
Third Party") relating to, or that would reasonably be expected to lead to: (i) a transaction or series of transactions
pursuant to which any Company Third Party acquires or would acquire, directly or indirectly, beneficial ownership (as defined in Rule 13d-3
under the 1934 Act) of more than twenty percent (20%) of the outstanding Company Shares or other equity securities of the Company (or
options, rights or warrants to purchase, or securities convertible into or exchangeable for, such securities) representing more than twenty
percent (20%) of the voting power of the Company, including pursuant to a stock purchase, merger, consolidation, tender offer, share exchange
or other transaction involving the Company or any of its Subsidiaries; (ii) any transaction or series of transactions pursuant to
which any Company Third Party acquires or would acquire, directly or indirectly, control of assets (including for this purpose the outstanding
equity securities of Subsidiaries of the Company and any entity surviving any merger or combination including any of them) of the Company
or its Subsidiaries representing more than twenty percent (20%) of the revenues, net income or assets (in each case, on a consolidated
basis) of the Company and its Subsidiaries, taken as a whole; or (iii) any disposition of assets representing more than twenty percent
(20%) of the revenues, net income or assets (in each case, on a consolidated basis) of the Company and its Subsidiaries, taken as a whole.
"Anti-Corruption Laws" means
any applicable Law relating to corruption, bribery, ethical business conduct, fraud, money laundering, political contributions, gifts
and gratuities, or improper payments, including but not limited to the U.S. Foreign Corrupt Practices Act of 1977, as amended, U.K. Bribery
Act 2010, and Laws implementing the Convention on Combating Bribery of Foreign Public Officials in International Business Transactions.
"Anti-Takeover Measure" shall
have the meaning set forth in Section 3.26.
"Antitrust Investigation" shall
have the meaning set forth in Section 7.01(d).
"Antitrust Laws" means the HSR
Act, the Sherman Act, the Clayton Act, the Federal Trade Commission Act and any other applicable Laws relating to antitrust or competition
regulation that are designed or intended to prohibit, restrict or regulate actions having the purpose or effect of monopolization or restraint
of trade or lessening competition through merger or acquisition.
"BaFin" means the German Federal
Financial Supervisory Authority (Bundesanstalt f r. Finanzdienstleistungsaufsicht).
"Business Day" means a day,
Last updated: Jun 12, 2025